Leukocytes and leukocyte-derived microparticles contain low levels of tissue factor (TF) and incorporate into forming thrombi. Although this circulating pool of TF has been proposed to play a key role in thrombosis, its functional significance relative to that of vascular wall TF is poorly defined. We tested the hypothesis that leukocyte-derived TF contributes to thrombus formation in vivo. Compared to wild-type mice, mice with severe tissue factor deficiency (i.e.
Introduction
Tissue factor (TF) is a membrane-bound protein that forms a complex with blood coagulation factor VII to activate the coagulation protease cascade. 1, 2 In a normal artery, TF is expressed primarily in the adventitia and is inaccessible to flowing blood. Hemostasis after vascular injury is initiated when TF within the vessel wall is exposed to factor VII in plasma. TF expression is markedly increased within arterial atherosclerotic plaques, where it is thought to play a key role in triggering intravascular clotting after spontaneous plaque rupture. [3] [4] [5] Extension of the thrombus into the blood vessel lumen can obstruct blood flow, causing unstable angina and acute myocardial infarction. The TF/factor VIIa complex also plays a major role in the pathogenesis of venous thrombosis, a leading cause of morbidity and mortality. 6 In distinction to its role in thrombus initiation, the role of vessel wall-derived TF in thrombus propagation is not as well defined, since it may become inaccessible to circulating clotting factors as rapid deposition of platelets and fibrin on the exposed vessel surface results in physical separation of vessel wall TF from circulating blood. 7, 8 Recent studies indicate that a small amount of TF is detectable in the blood, and is capable of supporting clot formation in vitro. 7 Plasma TF levels are elevated in patients with unstable angina and acute myocardial infarction and correlate with adverse outcomes. [9] [10] [11] Hence, it has been proposed that a circulating pool of TF may play an important role in thrombus propagation by sustaining thrombin production on the clot surface, ultimately leading to the development of an occlusive thrombus. 8, 12 Although the cellular origin of circulating TF is unknown, there is evidence to suggest that leukocytes and leukocyte-derived microparticles are a major source. Leukocytes are the only blood cells known to synthesize TF. 12, 13 LeukocyteFor personal use only. on November 16, 2017. by guest www.bloodjournal.org From associated TF is present in clots formed in vitro and in human thrombi in situ. 7, 14 Furthermore, TF can be transferred from leukocytes to platelets in vitro via an interaction involving CD-15-expressing membrane microparticles and P-selectin. 15 Thus, based on in vitro studies, coupled with the observation of increased levels of circulating TF-positive leukocyte-derived microparticles in various thrombotic diseases, [16] [17] [18] [19] there is a growing body of evidence in favor of a role for leukocyte-derived TF in thrombosis. However, there are no existing data that clearly define the functional role of leukocyte-derived TF, particularly its contribution to thrombus formation relative to that of TF derived from the blood vessel wall.
We have conducted a series of in vivo experiments to examine the role of TF originating from leukocytes or leukocyte-derived microparticles in thrombosis after vascular injury. We employed a bone marrow transplantation strategy to alter TF expression within leukocytes to determine whether TF synthesized by the leukocyte is an important contributor to thrombosis.
As targeted disruption of the TF gene in mice yields an embryonically lethal phenotype, [20] [21] [22] we utilized transgenic mice with severe TF deficiency as a source of TF-deficient hematopoietic stem cells. 23 We hypothesized that if circulating leukocytes are an important source of thrombogenic TF, then reduction of TF expression within this pool would limit thrombus growth. Similarly, we hypothesized that restoration of wild-type leukocyte TF expression in mice with very low levels of vessel wall TF would augment thrombus formation. However, our results obtained using models of macrovascular arterial and venous thrombosis, suggest that the TF driving thrombus formation is of non-leukocyte origin. were added to the plasma samples.
Procoagulant Activity of Plasma Microparticles and Whole Blood Cell Membranes.
Microparticles and whole blood cell membranes were isolated from mouse plasma as described previously. 29, 30 The total protein concentration of microparticles and blood cell membrane preparations were determined using BCA reagent (Pierce). Forty microliters of the microparticle suspension (2.9 mg/mL), blood cell membrane suspension (8 mg/mL), carotid artery homogenate (10 µg/mL), or vehicle was mixed with 40 µL of citrated pooled wild-type mouse plasma and 40 µL of CaCl 2 (final concentration 5 mM), and time to clot formation was measured as for the macrophage assay. Clotting times were expressed in relative units/ mg protein based on a standard curve of serially diluted mouse brain extract.
Carotid Artery Thrombosis Model. Photochemical vascular injury to the mid portion of the common carotid artery was performed on pentobarbital-anesthetized mice as previously described. 31 Flow was monitored continuously from the onset of injury until stable occlusion occurred (defined as no flow for > 10 min), or for 120 min if occlusion did not occur. Occlusion time was defined as the interval between the initiation of vascular injury and the onset of stable occlusion. For the purpose of calculating mean occlusion times, animals that did not occlude were assigned an occlusion time of 120 min.
Venous Thrombosis Model.
Mice were anesthetized with an inhalation mixture of isoflurane gas (1.5% to 2%) in oxygen. A midline laparotomy was performed and the inferior vena cava (IVC) was ligated immediately inferior to the renal veins, as described previously. 32 The abdomen was closed and the animal was recovered. After 48 hours, the IVC was harvested and weighed, and the weight was normalized to vein length (mg/cm) to calculate the mass of thrombus that formed during the period of venous stasis. 
Results
Arterial and venous thrombosis are impaired in low-TF mice. There was a marked effect of reduced total TF expression on thrombosis. After photochemical carotid artery injury, all wildtype mice developed arterial thrombotic occlusion within 75 minutes (mean occlusion time of 43.5 ± 6.0 min, n=9, Figure 1A and B). In comparison, the mean occlusion time of low-TF mice was 98.7 ± 15.1 min (n=7, p=0.003 vs. wild-type), a value that likely underestimates the difference between the two groups, since 5 of 7 low-TF mice failed to occlude during 120 minutes of monitored flow.
In an IVC ligation model of venous thrombosis, the mean thrombus mass of low-TF mice (6.9 ± 2.1 mg/cm, n=9) was markedly reduced compared to that of wild-type animals (20.4 ± 2.7 mg/cm, n=10, p=0.002, Figure 1C) . A thrombus was grossly visible in only 1 of 9 low-TF animals compared to 9 of 10 wild-type mice.
Bone marrow transplantation successfully reconstitutes recipient bone marrow without altering vascular wall TF activity. Genomic DNA was prepared from peripheral blood cells obtained 6 weeks after transplantation. PCR analysis failed to detect recipient mouse cell DNA, while demonstrating a strong signal attributable to transplanted cells ( Figure 2 (Table) . The only significant differences in transplanted groups compared to wild-type non-transplanted mice were higher total leukocyte counts in wild-type mice transplanted with wild-type bone marrow and low-TF mice transplanted with wild-type marrow and higher monocyte counts in low-TF mice transplanted with wild-type marrow.
To determine if transplanted bone marrow cells were capable of expressing TF after engraftment, TF activity of peritoneal macrophages was assessed. TF activity was significantly lower in macrophages from low-TF mice compared to wild-type mice ( Figure 3 ). However, TF activity of macrophages from low-TF mice transplanted with wild-type bone marrow was similar to that of wild-type animals (both with and without LPS stimulation), suggesting that leukocyte TF activity was appropriately altered by bone marrow transplantation.
To assess the functional pool of TF in the blood vessel wall, the procoagulant activities of homogenized carotid arteries were analyzed in an amidolytic assay that measures factor Xa generation ( Figure 4A ). Mean carotid TF activity was markedly lower in low-TF arteries compared to wild-type arteries, but was not significantly different between mice that had undergone bone marrow transplant and their non-transplanted, recipient-genotype-matched counterparts. These results, which were corroborated in a clotting based assay that utilized murine plasma ( Figure 4B ), suggest that bone marrow transplantation did not significantly alter vascular wall TF expression.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Modulation of the leukocyte pool of tissue factor does not significantly alter arterial or venous thrombosis. The mean carotid artery occlusion time of wild-type mice transplanted with wild-type bone marrow (51.5 ± 7.9 min, n=17) did not differ significantly from that of wild-type non-transplanted mice (43.5 ± 6.0 min, p=0.47). The mean occlusion time of wild-type mice transplanted with low-TF marrow (40.9 ± 6.9 min, n=17, Figure 5A and B) was not significantly different from that of wild-type mice (43.5 ± 6.0 min, p=0.88) or from that of wild-type mice transplanted with wild-type bone marrow (51.5 ± 7.9 min, p=0.30). Therefore, in the presence of normal vessel wall TF expression, a reduction of the leukocyte pool of TF did not affect the development of an occlusive arterial thrombus. In the converse transplantation strategy, low-TF mice were transplanted with wild-type bone marrow. This group had a prolonged mean occlusion time (89.9 ± 9.5 min, n=8) compared to wild-type mice (p<0.01) or wild-type mice transplanted with wild-type marrow (p=0.05), which was not significantly shorter than that of non-transplanted low-TF mice (98.7 ± 15.1 min, p=0.16). As a whole, the bone marrow transplantation experiments described above did not support a significant role of the leukocyte pool of TF in determining the rate of occlusive thrombus formation after arterial injury.
We also studied carotid artery thrombosis in LDLR -/-mice with hyperlipidemia, a condition associated with increased circulating TF activity in humans. 35, 36 Mean plasma total cholesterol levels were 862 ± 112 and 727 ± 109 mg/dL in LDLR -/-mice transplanted with wildtype vs. low-TF marrow, respectively (p = 0.4). Thrombosis was accelerated in both groups of LDLR -/-mice compared to wild-type mice, consistent with other studies. 36 However, the mean occlusion time in LDLR -/-mice transplanted with low-TF bone marrow (14.8 ± 2.6 min, n=5) did not differ significantly from that of LDLR -/-mice transplanted with wild-type bone marrow (16 ± 2.6 min, n=5, p=0.76).
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Inferior vena cava ligation experiments indicated that TF is important in venous thrombosis and that the major source of TF driving venous thrombus generation is the vessel wall and not leukocytes. Two days after IVC ligation, there was no significant difference in mean thrombus mass between wild-type mice transplanted with low-TF marrow (16.4 ± 2.4 mg/cm, n=10, Figure 5C ) or wild-type marrow (15.9 ± 2.5 mg/cm, n=9, p=1.0). In contrast, low-TF mice transplanted with wild-type marrow demonstrated a marked reduction in mean thrombus mass (3.8 ± 0.8 mg/cm, n=7) compared to wild-type mice transplanted with wild-type marrow (p=0.01), indicating that restoration of normal expression of TF in leukocytes did not enhance thrombus formation in low-TF mice. Overall, these results were concordant with those obtained in the arterial thrombosis model.
Plasma factor Xa generation and procoagulant activities of blood cell membranes and
microparticles do not differ between wild-type and low-TF mice. To complement our thrombosis experiments, we performed a series of in vitro studies examining the TF activity present in the blood and blood vessel wall. We used an amidolytic assay that measures factor Xa generation in plasma in the presence of CTI, an inhibitor of the intrinsic coagulation pathway, to examine plasma TF activity. There was no significant difference in factor Xa generation between wild-type and low-TF plasmas (1.88 ± 0.21 and 1.67 ± 0.16 mOD/minute respectively, p=0.43), and addition of rNAPc2 had no effect in either group (1.68 ± 0.21 [p=0.68] and 1.61 ± 0.35 mOD/minute [p=0.29]). Addition of a trace amount (0.2 µL) of wild-type mouse brain extract to the plasma potently accelerated factor Xa generation (to 20.3 ± 1.8 mOD, n=4), and this signal was almost completely inhibited by rNAPc2 (3.1 ± 0.3 mOD/min, n=3).
Ultracentrifugation of wild-type plasma to deplete it of microparticles did not reduce its low
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From level of factor Xa generating capacity. These results suggested that the concentration of active TF in mouse plasma, including its microparticle fraction, was very low.
There has been considerable interest in the role of TF in generating the procoagulant activity associated with plasma microparticles and blood cells. We used a clotting-based assay to examine the procoagulant activities of plasma microparticles and peripheral blood cell membranes prepared from wild-type and low-TF mice. The addition of wild-type microparticles to plasma accelerated fibrin formation, yielding a mean clotting time of 60 ± 3 sec (n=8) vs. 119 ± 13 sec (n=4) for control reactions. Similarly, depleting wild-type pooled plasma (prepared from 25 mice) of microparticles by ultracentrifugation prolonged the mean clotting time to 294 sec, compared to 130 sec for non-ultracentrifuged pooled plasma. However, the mean procoagulant activities (expressed as units of TF/mg protein) of wild-type plasma microparticles (1.33 ± 0.23 U/mg) and blood cell membranes (0.003 ± 0.001 U/mg) did not differ from those of low TF mice (1.68 ± 0.69 U/mg and 0.003 ± 0.001 U/mg respectively, p>0.3). In contrast, the mean procoagulant activity of carotid artery homogenates prepared from low-TF mice (1.80 ± 1.05 U/mg) was markedly lower than that of wild-type mice (121± 31 U/mg; p=0.01). These results, coupled with those of the amidolytic assay reported above (Figure 4) , indicate that the procoagulant activity of the arterial wall is largely TF-dependent. When compared on a per mg protein basis, the procoagulant activity of arterial wall homogenates from wild-type mice was 90-fold greater than that of circulating microparticles and over 1000-fold greater than that of blood cell membranes. Together, these in vitro data suggest that under basal conditions circulating tissue factor activity is very low and is markedly less than that present in the blood vessel wall.
Discussion
It is generally accepted that initial thrombus formation after vascular injury is triggered by TF present in the blood vessel wall.
1,2,37 However, it has been proposed that vessel wall TF is effectively prevented from contributing to subsequent thrombus growth after it is isolated from flowing blood by the mural thrombus itself. 8, 38 A better understanding of the factors that determine continued thrombus propagation after the initial wave of fibrin and platelet deposition is of critical importance, since thrombi that completely occlude blood flow within medium-and large-sized blood vessels play a major role in the pathogenesis of life-threatening vascular diseases such as acute myocardial infarction and stroke. The demonstration of TF in the blood, 7 as well as its deposition in thrombi, 14 has led to the hypothesis that a circulating pool of TF plays a significant role in thrombus growth by supporting continued factor X activation and thrombin generation on the clot surface. 7, 8 While the cellular origin of circulating TF remains elusive, there is substantial evidence from in vitro studies that favors leukocytes, or microparticles derived from leukocytes, as the major source. For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Ex vivo perfusion chamber studies utilizing blood from healthy individuals have suggested that leukocyte TF may contribute to thrombus development even under basal conditions. 7 Utilizing an arterial injury model that is sensitive to circulating coagulation factors, 25,39,40 our experiments suggest that the vascular wall, rather than the bone marrow, is the dominant source of TF that drives occlusive thrombus formation after injury to a medium-sized artery. Consistent with our results, recent intravital microscopy studies of thrombi forming in cremasteric arterioles detected TF predominantly at the thrombus-vessel wall interface, with very little on the luminal surface of the thrombus. 41, 42 However, a more recent study demonstrated Pselectin-dependent incorporation of TF-bearing microparticles, generated ex vivo by activation of mouse blood cells, into growing thrombi. 43 While these results suggest a role for circulating TF and P-selectin glycoprotein ligand-1-expressing microparticles of leukocyte origin in early thrombus formation in the mouse microcirculation, they do not provide direct evidence that circulating TF synthesized by leukocytes under basal conditions is a critical determinant of the formation of an occlusive thrombus relative to that of TF derived from the blood vessel wall.
Differences observed between this study and ours may be attributable to differences in the vascular bed studied, the nature and severity of vessel injury, and the time over which thrombus formation was monitored. The molecular mechanisms governing clot development are likely to differ in different sized blood vessels following varying degrees of vascular injury and therefore, the contribution of leukocyte-derived TF to thrombosis in animal studies may be highly model dependent. Further studies will be necessary to investigate the role of leukocyte-derived TF in microvascular thrombosis. Finally, it is important to recognize that there may be fundamental species differences in the contribution of different pools of TF to thrombus development between mice and humans.
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There are several potential explanations for our findings. First, it is possible that vascular wall TF may not be entirely walled-off by the forming clot. TF derived from cells within the vascular wall could be delivered to the surface of the thrombus by intermittent, flow-induced dislodgement of the upstream edge of the thrombus, allowing exposure and release of vascular wall TF into the blood. It is also possible that other factors, such as shear stress, thrombinindependent platelet activation, or the intrinsic coagulation system may play more important roles than circulating TF in determining thrombus formation in these models. 44 For example, factor XI appears to be essential for clot initiation after murine arterial injury, as well as clot propagation after TF-triggered clot formation within synthetic vascular grafts in primates. 45, 46 Another possibility is that the leukocyte pool of TF may play a role in thrombosis only under conditions in which the synthesis of TF by monocytes, the only blood cells capable of synthesizing TF, 12,13 is up-regulated. For example, monocyte TF expression is induced by lipopolysaccharide and may promote microvascular thrombosis associated with sepsis. 47 In addition, monocyte TF expression is substantially increased in acute myocardial infarction 48 and hyperlipidemia. 36 In a preliminary attempt to examine the potential effect of leukocyte-derived TF in hyperlipidemic animals, we studied thrombosis in a non-atherosclerotic portion of the common carotid artery in LDLR -/-mice transplanted with wild-type or low-TF marrow. We did not observe significant differences in thrombosis between these two groups. However, further studies will be necessary to more rigorously explore the importance of leukocyte TF under pathologic conditions, and to define its role in atherogenesis and plaque thrombogenicity.
The pathophysiology of venous thrombosis differs considerably from that of arterial thrombosis. Although endothelial disruption is characteristic, it is often less extensive than that which triggers arterial thrombosis. 49 Additionally, leukocyte adhesion and transmigration have been demonstrated as early events in the initiation of venous thrombosis. 49, 50 Thus, it has been proposed that circulating TF, perhaps derived from leukocytes, could be a key determinant of fibrin generation in this setting. 38, 51 Interestingly, a recent study demonstrated that inhibition of TF significantly reduced fibrin accumulation on a collagen-coated thread implanted into a rabbit vein. 52 Immunostaining revealed TF mostly associated with leukocytes within the thrombi.
While these studies suggest a potential role for circulating leukocyte-associated TF in venous thrombosis, they do not establish a cause-and-effect relationship between leukocyte TF expression and thrombus growth. Our results do not support an essential role for leukocytederived TF in the development of stasis-induced venous thrombosis, as modulation of leukocyte TF expression by bone marrow transplantation had no significant effect on thrombosis, neither in the presence of normal nor reduced vascular wall TF.
Although our experiments suggest that the vascular wall is the dominant source of thrombogenic TF in medium-sized and large blood vessels, they do not exclude a minor role of leukocyte-derived TF in thrombus formation. Similarly, they do not exclude a potential role for a circulating pool of TF in thrombosis, since this pool could originate from sources other than the bone marrow. Several recent reports indicate that platelets contain functionally active TF that is released upon platelet activation in vitro. 12, 53, 54 However, no TF antigen or mRNA is detectable in megakaryocytes, 12, 54 suggesting that platelet TF is acquired from elsewhere. Potential cellular sources of circulating TF other than leukocytes include vascular endothelial cells and smooth muscle cells, both of which are capable of releasing TF-bearing membrane microparticles. 16, 18, [55] [56] [57] In fact, high levels of procoagulant microparticles of endothelial cell origin have been detected in the blood of patients with acute coronary syndromes. 58 Furthermore, TF procoagulant activity measured in whole blood from patients with severe bone marrow aplasia is only reduced by 45%. 59 While there has been intense interest in the biologic function of circulating TF, a major challenge in the field has been the development of assays for measuring TF activity in blood, particularly in the mouse. We found that murine plasma tissue factor activity under basal conditions was very low and did not differ between wild-type mice and low-TF mice. These results are consistent with a recent report suggesting that the concentration of active TF in human plasma is below 20 fM. 60 We also were unable to discern differences between the procoagulant activities of plasma microparticles and peripheral blood cell membranes of wild-type mice vs.
low-TF mice. These results suggest that these components of blood may support clotting by mechanisms other than their TF activity, for example by providing a phospholipid surface to support assembly of coagulation complexes. Consistent with our data, a recent study concluded that the procoagulant activity of microparticles prepared from healthy human subjects was independent of their TF content. 61 Our in vitro studies also suggest that the TF activity present in the blood vessel wall vastly exceeds that present in blood components, further supporting the hypothesis that the blood vessel wall is the dominant source of thrombogenic TF. However, it must be emphasized that in vitro assessment of TF activity is difficult, and that in vitro assays may not provide the conditions necessary to activate encrypted TF within blood components.
Therefore, in vivo experiments, which were the main focus of our study, are essential to examine the biologic function of leukocyte-derived TF. We employed several functional assays to compare TF activities of tissue and blood samples from wild-type and low-TF mice, some of which employed mouse plasma and others purified human coagulation proteins. Human and mouse TF would not be expected to have identical specific activities in all of these assays, and it is therefore conceivable that there is some error in the comparisons of tissue factor activity between experimental groups expressing exclusively mouse vs. human TF. 
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